4SC AG Book/Share
What is the Book/Share of 4SC AG?
The Book/Share of 4SC AG is 0.76
What is the definition of Book/Share?
Book value per share is a company’s assets minus liabilities divided by the number of shares outstanding.
mrq (most recent quarter)
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Book/Share of companies in the Health Care sector on XETRA compared to 4SC AG
What does 4SC AG do?
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.
Companies with book/share similar to 4SC AG
- Farmmi Inc has Book/Share of 0.75
- Hennes & Mauritz AB has Book/Share of 0.75
- Guyana Goldfields has Book/Share of 0.76
- SEM has Book/Share of 0.76
- Euroland Corporate Societe anonyme has Book/Share of 0.76
- Goldshore Resources has Book/Share of 0.76
- 4SC AG has Book/Share of 0.76
- NovoCure Ltd has Book/Share of 0.76
- Japara Healthcare has Book/Share of 0.76
- Acorn Capital Investment Fund has Book/Share of 0.76
- Taizhou Water Co Ltd has Book/Share of 0.76
- Lyra Therapeutics has Book/Share of 0.76
- Vulcan Steel Ltd has Book/Share of 0.76